Hagens Berman flags GRAIL class action ahead of Aug. 4, 2026 deadline

Hagens Berman Sobol Shapiro LLP said a securities fraud class action has been filed against GRAIL, Inc. and is urging investors with substantial losses to come forward before the August 4, 2026 lead plaintiff deadline. The proposed class period covers investors who bought or acquired GRAIL common stock between May 13, 2025 and February 19, 2026. The complaint alleges GRAIL and certain senior executives misled investors about the design, progress and efficacy of the NHS-Galleri cancer screening trial by asserting that a three-year follow-up period could demonstrate a statistically significant reduction in late-stage cancers while allegedly withholding data and internal indications that a longer follow-up was needed. Hagens Berman points to February 19, 2026, when GRAIL announced top-line results showing the trial failed to meet its primary endpoint and said it "probably should have allowed for a longer follow-up period." GRAIL shares then fell 50.55% in one session, from $101.53 to $50.21 on February 20, 2026, erasing more than $2.2 billion in market value, according to the release.